These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Another option for less than 50 T4 cells.
    Journal: Treat Rev; 1995; (no 19):3. PubMed ID: 11362755.
    Abstract:
    People with fewer than 50 T4 cells may be eligible to participate in a clinical trial examining three drugs administered singly or in combination. The drugs are Crixivan (MK-639), AZT, and 3TC. Participants will receive either AZT plus 3TC; Crixivan, a protease inhibitor; or Crixivan plus AZT plus 3TC. Participants must have taken and tolerated AZT for more than six months at the standard dose. AZT-naive individuals are eligible for a special, open-label arm of the study.
    [Abstract] [Full Text] [Related] [New Search]